TrialThe Lancet. Haematology2026

Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial.

Alina Markova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.